Playback speed
10 seconds
ESMO 2023 Insights: "Alliance A021602 Study - Cabozantinib vs. Placebo for Advanced Neuroendocrine Tumours After Progression on Prior Therapy"
By
ecancer
FEATURING
Jennifer Chan
By
ecancer
FEATURING
Jennifer Chan
0 views
November 14, 2023
Comments 0
Login to view comments.
Click here to Login